Document Detail

Celecoxib to prevent restenosis--results from the COREA-TAXUS trial.
MedLine Citation:
PMID:  18201156     Owner:  NLM     Status:  MEDLINE    
Celecoxib inhibits Akt, which is stimulated during restenosis. Cell and animal studies showed that celecoxib inhibited Akt stimulation and restenosis. Recently, the COREA-TAXUS (Effect of Celecoxib on Restenosis after Coronary Angioplasty with Taxus stent) trial was performed in subjects with angina or a positive-stress test receiving paclitaxel-eluting stents. The primary end point at 6 months was the in-stent, late luminal loss, which was 0.49 mm in the celecoxib-treated group; less than the 0.75 mm in the group not treated with celecoxib. The rate of revascularisation of the target lesion was lower in celecoxib-treated subjects (5%) than in the untreated subjects (15%). In conclusion, this is an excellent demonstration of translating a mechanism of action of a drug into a clinical use.
Sheila A Doggrell
Related Documents :
10831516 - Edge restenosis after implantation of high activity (32)p radioactive beta-emitting ste...
21347366 - Cell origin of human mesenchymal stem cells determines a different healing performance ...
21107326 - Plasma heparin cofactor ii activity is inversely associated with left atrial volume and...
21519356 - Heart rate: a forgotten link in coronary artery disease?
11232216 - Measurement of the renin-angiotensin system in heart failure.
12950546 - Evaluation of myocardial performance with conventional single-site ventricular pacing a...
Publication Detail:
Type:  In Vitro; Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  9     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-01-18     Completed Date:  2008-04-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  339-41     Citation Subset:  IM    
RMIT University, Discipline of Pharmaceutical Sciences, School of Medical Sciences, Bundoora, Victoria 3083, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Restenosis / drug therapy,  prevention & control*
Pyrazoles / standards*,  therapeutic use*
Randomized Controlled Trials as Topic / methods,  trends*
Sulfonamides / standards*,  therapeutic use*
Reg. No./Substance:
0/Pyrazoles; 0/Sulfonamides; 169590-42-5/celecoxib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fexofenadine in pediatrics: oral tablet and suspension formulations.
Next Document:  Democracy: the forgotten determinant of mental health.